Taysha Gene Therapies is a clinical-stage biotechnology company (Dallas, TX with a laboratory in Morrisville, NC) developing AAV-based gene therapies for rare monogenic diseases of the central nervous system. Its lead program, TSHA-102, targets Rett syndrome and has completed dosing in the REVEAL pivotal trial. - View it on GitHub